Inhaled Tobramycin in BPD - Trial NCT04560179
Access comprehensive clinical trial information for NCT04560179 through Pure Global AI's free database. This Phase 1 trial is sponsored by Erik Allen Jensen and is currently Not yet recruiting. The study focuses on Bronchopulmonary Dysplasia. Target enrollment is 54 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Erik Allen Jensen
Children's Hospital of Philadelphia
Timeline & Enrollment
Phase 1
Jan 01, 2022
Dec 31, 2023
Primary Outcome
Composite safety endpoint
Summary
This study is an open-label, phase 1, inter-patient dose escalation feasibility trial seeking
 establish preliminary tolerability, efficacy, and pharmacokinetic data for up to 4 different
 doses of inhaled tobramycin administered to very preterm infants with BPD who are receiving
 invasive mechanical ventilation and have a pathogenic Gram-negative organism detected by
 tracheal aspirate culture.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT04560179
Non-Device Trial